相关实验视频
Updated: Jul 4, 2025

08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
15.8K
在辅助黑色素瘤中,进展/无复发生存率为2
Ryan C Augustin1, Jason J Luke1
1UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh.
NEJM evidence
|February 6, 2024
概括
布罗利祖马布 (抗编程细胞死亡蛋白1) 为III阶段黑色素瘤患者提供了持久的无复发生存. 这种免疫检查点抑制剂治疗在预防黑色素瘤复发和远程转移方面显示出显著的长期益处.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 第三阶段黑色素瘤的特征是扩散到区域淋巴结或皮肤,这给临床带来了重大挑战.
- 免疫检查点抑制剂 (ICI) 已成为晚期黑色素瘤的有希望的治疗策略.
- 在III期黑色素瘤中ICI的长期结果数据对于指导临床实践至关重要.
相关概念视频
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Skin Cancer
4.1K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.1K
Cancer Survival Analysis
348
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
348

